Imatinib, a small-molecule ABL kinase inhibitor, is a highly effective therapy for early-phase
chronic myeloid leukaemia (CML), which has constitutively active ABL kinase activity owing …

Recent studies have identified primitive, malignant stem cells which have entered the G0-
phase of the cell cycle to become'quiescent'and which are present, in small numbers, in all …

The leukemic stem cells in patients with chronic myeloid leukemia (CML) are well known to
be clinically resistant to conventional chemotherapy and may also be relatively resistant to …

There are a number of leukemogenic protein-tyrosine kinases (PTKs) associated with
leukemic transformation. Although each is linked with a specific disease their functional …

Background Imatinib mesylate treatment causes remissions in a majority of patients with
chronic myeloid leukemia (CML), but relapses are an increasing problem. We hypothesized …

The acquisition of mutations within the BCR-ABL1 kinase domain is frequently associated
with tyrosine kinase inhibitor (TKI) failure in chronic myeloid leukemia. Sensitive sequencing …

BCR/ABL kinase–positive chronic myelogenous leukemia (CML) cells display genomic
instability leading to point mutations in various genes including bcr/abl and p53, eventually …

Myeloproliferative disorders (MPD) are stem cell–derived clonal diseases arising as a
consequence of acquired aberrations in c-ABL, Janus-activated kinase 2 (JAK2), and …

BCR/ABL-induced chronic myeloid leukemia (CML) is a stem cell-induced but progenitor
cell-driven disease, which usually starts as a relatively benign chronic phase (CML-CP) …

Constitutively active tyrosine kinases promote leukemogenesis by increasing cell
proliferation and inhibiting apoptosis. However, mechanisms underlying apoptotic inhibition …